Breast Cancer: How to Reduce Your Risk — Prevention Science in 2025
The Global Scale of Breast Cancer
Breast cancer is the most commonly diagnosed cancer globally, with over 2.3 million new
cases in 2022 and more than 670,000 deaths. It accounts for approximately 1 in 4 cancers in
women worldwide. Despite these numbers, breast cancer is also one of the most
successfully treated cancers when detected early — 5-year survival for Stage 1 disease
exceeds 99% in high-income countries. The challenge is preventing advanced-stage
diagnosis through awareness, screening, risk modification, and chemoprevention.
In 2025, the science of breast cancer prevention — not just treatment — made significant
and tangible advances that offer genuine hope to high-risk women.
Understanding Your Risk: Who Gets Breast Cancer?
Breast cancer risk is multifactorial — a combination of genetic, hormonal, reproductive,
lifestyle, and environmental factors. Understanding individual risk is the foundation of
prevention:
Genetic Risk Factors
Mutations in BRCA1 and BRCA2 genes are the most powerful known genetic risk factors.
Women with BRCA1 mutations face a lifetime breast cancer risk of 60–80%. BRCA2
mutations confer 45–70% lifetime risk. PALB2, CHEK2, ATM, and other gene mutations also
increase risk, though less dramatically. Genetic testing is increasingly recommended for
women with family history of breast or ovarian cancer, and genetic counselling for carriers
has become standard of care.
Hormonal and Reproductive Factors
Estrogen exposure throughout life is a key driver of hormone-receptor positive breast
cancers (which account for 70–80% of cases). Risk is increased by early menarche (first
period before age 12), late menopause (after age 55), nulliparity (never having children), late
first pregnancy (after age 30), and exogenous hormone use. Conversely, breastfeeding is
protective — women who breastfeed for 12+ months have approximately 15–20% lower
breast cancer risk, with evidence suggesting each additional 12 months of breastfeeding
reduces risk by a further 4–5%.
Evidence-Based Lifestyle Risk Reduction
Large-scale epidemiological evidence and meta-analyses confirm several modifiable lifestyle
factors that meaningfully reduce breast cancer risk:
- Physical Activity: Women who engage in regular moderate-to-vigorous physical activit
(3–5 hours per week) have 20–30% lower breast cancer risk compared to sedentary women.
Exercise reduces circulating oestrogen, insulin, and inflammatory markers — all of which
promote breast cancer growth. Any amount of physical activity is beneficial, with dose-response
relationships confirmed.
- Healthy Body Weight: Obesity (especially post-menopausal obesity) is associated wit
20–40% higher breast cancer risk. Adipose tissue produces estrogen via aromatase activity —
excess body fat effectively acts as an endogenous estrogen supplement. Achieving and
maintaining a healthy BMI is one of the most impactful modifiable risk reduction strategies.
- Alcohol Limitation: Alcohol is a well-established breast cancer risk factor — even ligh
drinking (1 drink/day) increases risk by 7–10%. The mechanism involves alcohol-induced
elevation of circulating estrogens and direct DNA damage via acetaldehyde. There is no safe
threshold: the lowest risk is associated with no alcohol consumption.
- Non-Smoking: While the causal link between smoking and breast cancer is less stron
than for other cancers, heavy smoking particularly before first full-term pregnancy has been
associated with 15–25% increased risk in large cohort studies.
- Dietary Pattern: A Mediterranean-style diet rich in vegetables, legumes, fish, and health
fats is associated with 15–20% lower breast cancer incidence compared to Western dietary
patterns.
Chemoprevention: Drugs That Prevent Breast Cancer
For women at elevated risk (≥1.7% 5-year risk on the Tyrer-Cuzick or Gail model, or known
BRCA/genetic mutations), several chemoprevention strategies have Level 1 evidence:
▸ Tamoxifen: Reduces invasive breast cancer risk by 38–50% in high-risk pre-menopausal
women. A 2025 Phase 3 trial (TAM01) presented at ASCO showed that low-dose tamoxifen
(1mg or 5mg) is as effective as the standard 20mg dose after 7 years of follow-up, with
significantly fewer side effects — opening the door to chemoprevention for more women
who previously declined full-dose tamoxifen
▸ Aromatase inhibitors (anastrozole, exemestane, letrozole): For post-menopausal high-
risk women, 5 years of aromatase inhibitor therapy reduces breast cancer risk by
approximately 50%. These have become the preferred chemoprevention option in post-
menopausal women due to a more favourable side effect profile than tamoxifen
▸ Raloxifene: Alternative to tamoxifen for post-menopausal women, with 38% risk reduction
and lower risk of uterine cancer
2025 Breakthrough: The Preventive Breast Cancer Vaccine
One of the most exciting developments in breast cancer prevention is the Cleveland Clinic's
Phase 1 clinical trial of a preventive breast cancer vaccine — the first of its kind. The vaccine
targets alpha-lactalbumin, a protein expressed during lactation and on triple-negative breast
cancer (TNBC) cells but not in normal non-lactating adult breast tissue.
In December 2025, Cleveland Clinic published Phase 1 trial findings: 74% of participants (35
enrolled across three cohorts including BRCA/PALB2 carriers and early-stage TNBC
patients) developed an immune response to the vaccine. The vaccine was well tolerated,
with side effects limited to mild injection-site inflammation. Phase 2 trials — the first to
evaluate whether the vaccine actually prevents or reduces breast cancer recurrence — are
expected to begin in 2025–2026 and run for 2–3 years.
Beyond the alpha-lactalbumin vaccine, 15 breast cancer vaccine trials are currently active
globally, targeting HER2, MUC1, hTERT, and other breast cancer-associated proteins. The
field is moving from science fiction toward reality.
Advanced Treatment in 2025: Hope for All Stages
For those already diagnosed, 2025 brought significant advances:
▸ Trastuzumab deruxtecan (T-DXd/Enhertu) for HER2-positive and HER2-low metastatic
disease: The DESTINY-Breast09 trial produced the first clinically meaningful improvement
in 1st-line HER2+ outcomes in over a decade
▸ Triple-negative breast cancer (TNBC): The ASCENT-04 trial showed sacituzumab
govitecan plus pembrolizumab reduced progression/death risk by 35% versus
chemotherapy plus pembrolizumab. Datopotamab deruxtecan became the first ADC to
demonstrate overall survival benefit in 1st-line TNBC at ESMO 2025
▸ Circulating tumour DNA (ctDNA) liquid biopsies are enabling real-time treatment
monitoring and earlier switching of therapies in patients whose cancer develops resistance
▸ Scientists at the University of Pennsylvania reported in September 2025 that they can
now detect dormant breast cancer cells in survivors and potentially eliminate them with
repurposed drugs — a critical advance in preventing late recurrence
Key Prevention Actions: Your Personal Risk Reduction Plan
▸ Know your family history — ask about cancer in 1st and 2nd degree relatives
▸ Genetic counselling if family history includes breast, ovarian, or related cancers
▸ Regular mammography screening from age 40–50 (or earlier for high-risk women)
▸ Maintain healthy weight, particularly after menopause
▸ Exercise 150–300 minutes per week at moderate intensity
▸ Limit or eliminate alcohol consumption
▸ Breastfeed if possible
▸ Discuss chemoprevention with your doctor if you are at high risk
References
[1] Breast Cancer Research Foundation. 5 Breast Cancer Breakthroughs from 2025. bcrf.org, January
2026.
[2] DeCensi A et al. TAM01 Trial: Low-dose tamoxifen at 7-year follow-up. ASCO 2025 presentation.
[3] Mansour R, Abunasser M, et al. Update in chemoprevention for breast cancer. Front Oncol.
2025;15:1435253. doi:10.3389/fonc.2025.1435253.
[4] Cleveland Clinic. Preventive Breast Cancer Vaccine Phase 1 Findings. newsroom.clevelandclinic.org,
December 2025.
[5] Susan G. Komen. ESMO 2025: 4 Advances in Breast Cancer. komen.org, November 2025.
[6] IARC. Body Fatness and Cancer — Viewpoint of the IARC Working Group. NEJM. 2016;375:794-798.
[7] Hamajima N et al. Alcohol, tobacco and breast cancer — collaborative reanalysis. Br J Cancer.
2002;87:1234-1245. doi:10.1038/sj.bjc.6600596.